Video follow up or conventional clinical follow up in malignant gliomas undergoing adjuvant temozolomide therapy
- Conditions
- Health Condition 1: null- Patients with Intermediate -high grade glioma ( WHO grade 2- 4 gliomas undergoing adjuvant temozolomide therapy
- Registration Number
- CTRI/2017/01/007626
- Lead Sponsor
- Tata Memorial Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 65
1.Participants must be post radical chemoradiation for a histologically confirmed newly diagnosed grade II-IV Glioma.
2.Participants must warrant adjuvant temozolomide
3.Age : Any age above 18 years. No maximum age.
4.Post first 2 cycles of adjuvant temozolomide
5.ECOG performance status <=2
6.Feasibility of doing video call at native place. Either internet based video call service or a smartphone based video call service. For internet based service either presence of skype or any other equivalent service for video call. For smartphone based video call presence of either a 3G or 4G service. For internet based video call presence of a webcam based camera of 480 pixels or more. For smartphone based video call presence of a front facing camera of 1.3 megapixels or more.
7.Participants must have normal organ and marrow function as defined below:
a.Leukocytes>=2,500/mcL or ANC >= 1000
b.Platelets>=100,000/mcL
c.Total bilirubin < 1.5 Ã? institutional upper limit of normal
d.AST(SGOT)/ALT(SGPT)<=2.5 Ã? institutional upper limit of normal
e.Calculated Creatinine clearance > 30 ml/min
8.The effect of temozolomide chemotherapy on the developing human fetus are teratogenic. Hence women and men of reproductive age must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. .
9.Both men and women of all races and ethnic groups are eligible for this trial.
10.Willing and able to comply with all study requirements, including treatment (able to swallow tablets), able to be followed up at regular intervals and/or nature of required assessments (e.g. ability to undergo video follow up)
11.Ability to understand and the willingness to sign a written informed consent document
1.Participants who had life threatening complications either during CTRT with temozolomide or during first 2 cycles of temozolomide
2.Participants who are receiving any other investigational agents.
3.History of allergic reactions attributed to compounds of similar chemical or biologic composition to any agents used in study.
4.Uncontrolled intercurrent illness including, but not limited to, hypertension, tuberculosis, diabetes, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, renal failure (on dialysis), active gastrointestinal bleeding, cerebrovascular accidents, inflammatory bowel disease, known hyperkalemia ( CTCAE version 4.02 grade 3 or above which is persistent over 1 week) or psychiatric illness/social situations that would limit compliance with study requirements.
5.Pregnant women and breastfeeding women are excluded from this study because temozolomide has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants. These potential risks may also apply to other agents used in this study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Treatment plan for administration of temozolamide will be compared at the end of the study between the 2 approaches.Timepoint: 1 month
- Secondary Outcome Measures
Name Time Method 1.Agreement between different domains of treatment plan between VF & CCF <br/ ><br>2.To compare the patients satisfaction rate between VF & CCF <br/ ><br>3.To compare the direct cost between VF & CCFTimepoint: 1.1 month <br/ ><br>2.1 month <br/ ><br>3.1 month <br/ ><br>